Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Editorial overview: Peptides in cancer.

Whitfield J, Soucek L.

Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1. doi: 10.1016/j.coph.2019.06.001. [Epub ahead of print] No abstract available.

PMID:
31257021
2.

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaar5012. doi: 10.1126/scitranslmed.aar5012.

3.

Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.

Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R.

Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Epub 2019 Jan 10.

PMID:
30230537
4.

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.

Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L.

Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10.

5.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
6.

Drugging the 'undruggable' cancer targets.

Dang CV, Reddy EP, Shokat KM, Soucek L.

Nat Rev Cancer. 2017 Aug;17(8):502-508. doi: 10.1038/nrc.2017.36. Epub 2017 Jun 23. Review.

7.

Pancreatic cancer heterogeneity and response to Mek inhibition.

Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J.

Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5.

PMID:
28581516
8.

Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.

Maltais L, Montagne M, Bédard M, Tremblay C, Soucek L, Lavigne P.

PLoS One. 2017 Mar 28;12(3):e0174413. doi: 10.1371/journal.pone.0174413. eCollection 2017.

9.

Strategies to Inhibit Myc and Their Clinical Applicability.

Whitfield JR, Beaulieu ME, Soucek L.

Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Review.

10.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

11.

Ibrutinib repurposing: from B-cell malignancies to solid tumors.

Massó-Vallés D, Jauset T, Soucek L.

Oncoscience. 2016 Jun 10;3(5-6):147-8. doi: 10.18632/oncoscience.310. eCollection 2016. No abstract available.

12.

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.

Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J.

Oncotarget. 2016 May 24;7(21):31014-28. doi: 10.18632/oncotarget.8826.

13.

Live or Die: Choice Mechanisms in Stressed Cells.

Cecconi F, Soucek L, Taub DD, Ziparo E.

Mediators Inflamm. 2015;2015:454863. doi: 10.1155/2015/454863. Epub 2015 Oct 8. No abstract available.

14.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

15.

The effect of environmental chemicals on the tumor microenvironment.

Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan EP, Ryeom S, Salem HK, Scovassi AI, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH, Felsher DW.

Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.

16.

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L.

Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852.

17.

The estrogen receptor fusion system in mouse models: a reversible switch.

Whitfield J, Littlewood T, Evan GI, Soucek L.

Cold Spring Harb Protoc. 2015 Mar 2;2015(3):227-34. doi: 10.1101/pdb.top069815.

PMID:
25734072
18.

Tamoxifen administration to mice.

Whitfield J, Littlewood T, Soucek L.

Cold Spring Harb Protoc. 2015 Mar 2;2015(3):269-71. doi: 10.1101/pdb.prot077966.

PMID:
25734062
19.

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.

Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L.

Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632.

20.

The Myc world within reach.

Sodir NM, Soucek L.

Methods Mol Biol. 2013;1012:1-6. doi: 10.1007/978-1-62703-429-6_1.

PMID:
24006054
21.

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI.

Genes Dev. 2013 Mar 1;27(5):504-13. doi: 10.1101/gad.205542.112.

22.

Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.

Soucek L, Buggy JJ, Kortlever R, Adimoolam S, Monclús HA, Allende MT, Swigart LB, Evan GI.

Neoplasia. 2011 Nov;13(11):1093-100.

23.

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.

Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, Mantovani A, Locati M.

Blood. 2012 Jan 12;119(2):411-21. doi: 10.1182/blood-2011-02-339911. Epub 2011 Nov 8.

24.

Tumor microenvironment: becoming sick of Myc.

Whitfield JR, Soucek L.

Cell Mol Life Sci. 2012 Mar;69(6):931-4. doi: 10.1007/s00018-011-0860-x. Epub 2011 Oct 28. Review.

25.

The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.

Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S.

PLoS One. 2011;6(7):e22284. doi: 10.1371/journal.pone.0022284. Epub 2011 Jul 21.

26.

Endogenous Myc maintains the tumor microenvironment.

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L.

Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.

27.

Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.

Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y.

Anticancer Res. 2010 Oct;30(10):4193-200.

PMID:
21036740
28.

The ups and downs of Myc biology.

Soucek L, Evan GI.

Curr Opin Genet Dev. 2010 Feb;20(1):91-5. doi: 10.1016/j.gde.2009.11.001. Epub 2009 Dec 3. Review.

29.

Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation.

Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI.

Mol Cell Biol. 2009 Oct;29(19):5306-15. doi: 10.1128/MCB.01745-08. Epub 2009 Jul 27.

30.

Modelling Myc inhibition as a cancer therapy.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI.

Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.

31.

Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.

Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI.

Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30.

PMID:
17906636
32.

Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms.

Finch A, Prescott J, Shchors K, Hunt A, Soucek L, Dansen TB, Swigart LB, Evan GI.

Cancer Cell. 2006 Aug;10(2):113-20.

33.

Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.

Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI.

Cancer Res. 2006 May 1;66(9):4591-601.

34.

Temporal dissection of p53 function in vitro and in vivo.

Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI.

Nat Genet. 2005 Jul;37(7):718-26. Epub 2005 May 29.

35.

Omomyc expression in skin prevents Myc-induced papillomatosis.

Soucek L, Nasi S, Evan GI.

Cell Death Differ. 2004 Sep;11(9):1038-45.

36.

c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis.

Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM.

Oncogene. 2003 Aug 28;22(36):5707-11.

PMID:
12944920
37.

Myc-Is this the oncogene from Hell?

Soucek L, Evan G.

Cancer Cell. 2002 Jun;1(5):406-8. Review.

38.

Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.

Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S.

Cancer Res. 2002 Jun 15;62(12):3507-10.

39.

NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction.

Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, Soucek L, Mosca L, Levi A, Jucker R, Nasi S.

FEBS Lett. 2002 Jan 2;510(1-2):50-6.

40.

Making decisions through Myc.

Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L.

FEBS Lett. 2001 Feb 16;490(3):153-62. Review.

41.

Design and properties of a Myc derivative that efficiently homodimerizes.

Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S.

Oncogene. 1998 Nov 12;17(19):2463-72.

42.

[The practitioner and the popular medicine].

SOUCEK L.

Prakt Lek. 1954 Jun 20;34(12):287-8. Czech. No abstract available.

PMID:
13194482
43.

[Essay on hormonal therapy of whooping cough].

SOUCEK L.

Prakt Lek. 1954 Mar 20;34(6):135-8. Undetermined Language. No abstract available.

PMID:
13155397
44.

[Unnecessary pain in periodontology].

SOUCEK L.

Prakt Zubn Lek. 1954;2(6):137-40. Undetermined Language. No abstract available.

PMID:
13185909
45.

[Rapid development of roentgenographic pictures].

SOUCEK L.

Prakt Zubn Lek. 1954;2(3):70-2. Undetermined Language. No abstract available.

PMID:
13177309
46.

[Patients suspected of Coxsackie virus infection].

SOUCEK L.

Prakt Lek. 1953 Sep 5;33(16-17):379-80. Undetermined Language. No abstract available.

PMID:
13100220
47.

[Photography in dentistry].

SOUCEK L.

Cesk Stomatol. 1952 Dec;52(12):451-60. Undetermined Language. No abstract available.

PMID:
13033045
48.

[Frequency, prevention, diagnosis, and therapy of oral cancer].

SOUCEK L.

Cesk Stomatol. 1952 Jul-Aug;52(7-8):274-81. Undetermined Language. No abstract available.

PMID:
12998076
49.

[Flying as a remedy against whooping cough].

SOUCEK L.

Pediatr Listy. 1951 May-Jun;6(3):158-65. Undetermined Language. No abstract available.

PMID:
14863986
50.

[Malocclusion caused by deciduous teeth].

SOUCEK L.

Cesk Stomatol. 1950 Jul-Aug;50(7-8):292-6. Undetermined Language. No abstract available.

PMID:
14801812

Supplemental Content

Loading ...
Support Center